Canaccord Genuity Reiterates a 'Buy' on Avanir Pharmaceuticals (AVNR); Good Nuedexta Trends Continues, Phase 2 Progress
Tweet
Share
E-mailGet Alerts AVNR Hot Sheet
Price: $16.96 --0%
Rating Summary:
4 Buy, 3 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Rating Summary:
4 Buy, 3 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Join SI Premium – FREE
Canaccord Genuity reiterates a 'Buy' on Avanir Pharmaceuticals (NASDAQ: AVNR) price target of $6.00.
Analyst, Ritu Baral, said, "Reiterate rating and price target on Nuedexta’s steady, continued growth, robust peak sales estimate. Nuedexta is AVNR’s drug for pseudo-bulbar affect, emotional lability seen in stroke, traumatic brain injury and other neurodegenerative disorders. Launch has been modest but steady, and we see new positive trends in long-term care use. Our peak annual sales estimates are $350M US, $300M EU."
"Phase 2 MS Pain PRIME trial well underway; PBA prevalence data from PRISM registry expected in 2012. We expect PRISM and PRIME data (H2/13) to be sales and stock drivers."
For an analyst ratings summary and ratings history on Avanir Pharmaceuticals click here. For more ratings news on Avanir Pharmaceuticals click here.
Shares of Avanir Pharmaceuticals closed at $3.17 yesterday.
Analyst, Ritu Baral, said, "Reiterate rating and price target on Nuedexta’s steady, continued growth, robust peak sales estimate. Nuedexta is AVNR’s drug for pseudo-bulbar affect, emotional lability seen in stroke, traumatic brain injury and other neurodegenerative disorders. Launch has been modest but steady, and we see new positive trends in long-term care use. Our peak annual sales estimates are $350M US, $300M EU."
"Phase 2 MS Pain PRIME trial well underway; PBA prevalence data from PRISM registry expected in 2012. We expect PRISM and PRIME data (H2/13) to be sales and stock drivers."
For an analyst ratings summary and ratings history on Avanir Pharmaceuticals click here. For more ratings news on Avanir Pharmaceuticals click here.
Shares of Avanir Pharmaceuticals closed at $3.17 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Viking Holdings (VIK) PT Raised to $82 at Mizuho
- Rockwell Automation (ROK) PT Lowered to $490 at DA Davidson
- Deere (DE) PT Raised to $585 at JPMorgan
Create E-mail Alert Related Categories
Analyst CommentsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
